Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback